Is your patient a candidate for a clinical trial?

Referring your patient
The UPMC Heart and Vascular Institute is a leader in conducting research studies and clinical trials to better understand and treat cardiovascular disease.

To refer a patient, please contact the study or trial coordinator or email VascularSurgeryResearch@upmc.edu.

For more information about the UPMC Heart and Vascular Institute, please call 412-802-3333 or visit UPMC.com/HVI.

Zenith® Low Profile AAA Endovascular Graft Clinical Study:
Zenith® Low Profile AAA Endovascular Graft used in conjunction with the Zenith® Spiral-Z™ AAA Iliac Leg Graft.

**Inclusion criteria:** Non-aneurysmal infrarenal aortic segment (neck) proximal to the aneurysm with a length of at least 15 mm, iliac artery distal fixation site > 10 mm in length and 7.5-20 mm in diameter.

**Principal Investigator:** Michael Singh, MD
**Contact:** Caroline Kissell, 412-235-1304

Zenith® p-Branch™ Pivotal Study:
Clinical investigation intended to evaluate the safety and effectiveness of the Zenith® p-Branch™ in combination with Atrium iCAST™ covered stents for the treatment of pararenal or juxtarenal aortic aneurysms.

**Inclusion criteria:** Patients with a pararenal or juxtarenal abdominal aortic aneurysm (AAA) ≥ 5.0 cm in diameter with anatomy suitable for treatment with the Zenith® p-Branch™.

**Principal Investigator:** Michael Singh, MD
**Contact:** Caroline Kissell, 412-235-1304

PRESERVE-Zenith® Iliac Branch Clinical Study:
Clinical study to evaluate the safety and effectiveness of the Zenith® Branch Endovascular Graft–Iliac Bifurcation.

**Inclusion criteria:** Patients with an aortoiliac or iliac aneurysm, an insufficient distal sealing site within the common iliac artery, and having morphology suitable for endovascular repair.

**Principal Investigator:** Michael Singh, MD
**Contact:** Caroline Kissell, 412-235-1304

2017 Vascular Surgery Clinical Trials

---

Principal Investigator: Michael Singh, MD
**Contact:** Patty Dragone, 412-623-8486
**SeCure: A Prospective Safety and Effectiveness Study:**
VenaCure Endovenous Laser Treatment (EVLT) 400 µm Fiber Procedure Kit for Treatment of Incompetent Perforator Veins: Angiodynamics 400 µm fiber for ablation of incompetent perforating veins (IPV) in patients with advanced venous disease.

**Inclusion criteria:** Age 18 or older, refractory symptomatic disease (CEAP Class 4b to Class 6), palpable pedal pulses, and any pathologic superficial veins must be treated previously eliminated at least more than 30 days prior to the study procedure.

**Principal Investigator:** Eric Hager, MD  
**Contact:** Caroline Kissell, 412-235-1304

**BEST-CLI Trial:**
Randomized, multicenter, controlled trial to compare best endovascular versus best surgical therapy in patients with critical limb ischemia.

**Inclusion criteria:** Infrainguinal arterial occlusive disease and critical limb ischemia (CLI) - arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford categories 4-6. Atherosclerotic, infrainguinal PAD. Candidate for both open and endovascular infrainguinal revascularization.

**Principal Investigator:** Rabih Chaer, MD  
**Contact:** Patty Dragone, 412-623-8486

**COOK IVC Filter Study:**
Clinical investigation plan to further evaluate the safety and effectiveness of Cook’s permanent and retrievable inferior vena cava (IVC) filters (specifically, the Günther Tulip® and the Cook Celect® filters).

**Inclusion criteria:** Patients in need of temporary or permanent IVC filter placement for the prevention of pulmonary embolism (PE).

**Principal Investigator:** Rabih Chaer, MD  
**Contact:** Caroline Kissell, 412-235-1304

**Aortic Wall Behavior as a Predictor of Aortic Aneurysm Growth and Rupture:**
Study of the metabolic processes within the aortic wall through microbubble ultrasound and serum biomarkers to identify vulnerable aortic wall characteristics and patients who are at risk of AAA growth or rupture.

**Inclusion criteria:** Unrepaired infrarenal AAA > 4cm.

**Principal Investigator:** Rabih Chaer, MD  
**Contact:** Patty Dragone, 412-623-8486

**Critical Limb Ischemia (CLI) in Patients with Femoropopliteal Occlusive Disease Treated with Drug Coated Balloon (DCB) Angioplasty:**
Pilot study to evaluate if there is a direct association between paclitaxel and wound healing in patients with CLI.

**Inclusion criteria:** Femoropopliteal arterial occlusive disease and CLI with tissue loss (Rutherford Classification of 5 or 6). All activities are standard of care with the exception of sending the debrided tissue sample for specialized staining to evaluate for paclitaxel crystals.

**Principal Investigator:** Rabih Chaer, MD  
**Contact:** Ali Arak, 412-623-8443

**Registry of Transcarotid Artery Revascularization (TCAR) in Patients with Significant Carotid Artery Disease:**
Registry to confirm the safety and effectiveness of the less-invasive TCAR procedure using the ENROUTE® Transcarotid Neuroprotection and Stent System to provide cerebral (brain) embolic protection during carotid artery revascularization in subjects at high risk for complications from traditional CEA. The TCAR procedure temporarily reverses blood flow to the brain during the carotid intervention to reduce the incidence of procedural embolic stroke while delivering balloons and a stent to stabilize the plaque to prevent a future stroke. All procedures are standard of care. Study follow-up is one month in duration.

**Principal Investigator:** Rabih Chaer, MD  
**Contact:** Patty Dragone, 412-623-8486

**Standard vs. UltrasouNd-asSisted CathEter Thrombolysis for Acute Submassive Pulmonary Embolism (SUNSET sPE) Trial:**
Randomized trial on intermediate risk pulmonary embolism comparing standard catheter vs. ultrasound assisted thrombolysis. The Pulmonary Embolism Response Team (PERT) of UPMC has recently started actively enrolling patients.

**Principal Investigators:** Efthymios Avgerinos, MD  and Rabih Chaer, MD  
**Contact:** Ali Arak, 412-623-8443